title: First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease.
abstract: A neonate born to an Ebola virus-positive woman was diagnosed with Ebola virus infection on her first day of life. The patient was treated with monoclonal antibodies (ZMapp), a buffy coat transfusion from an Ebola survivor, and the broad-spectrum antiviral GS-5734. On day 20, a venous blood specimen tested negative for Ebola virus by quantitative reverse-transcription polymerase chain reaction. The patient was discharged in good health on day 33 of life. Further follow-up consultations showed age-appropriate weight gain and neurodevelopment at the age of 12 months. This patient is the first neonate documented to have survived congenital infection with Ebola virus.
authors.affiliation: Médecins Sans Frontières, Brussels.
authors.forename: Jenny
authors.initials: J
authors.lastname: Dörnemann
authors.affiliation: Médecins Sans Frontières, Brussels.
authors.forename: Chiara
authors.initials: C
authors.lastname: Burzio
authors.affiliation: Médecins Sans Frontières, Brussels.
authors.forename: Axelle
authors.initials: A
authors.lastname: Ronsse
authors.affiliation: Médecins Sans Frontières, Brussels.
authors.forename: Armand
authors.initials: A
authors.lastname: Sprecher
authors.affiliation: Médecins Sans Frontières, Brussels.
authors.forename: Hilde
authors.initials: H
authors.lastname: De Clerck
authors.affiliation: Médecins Sans Frontières, Brussels.
authors.forename: Michel
authors.initials: M
authors.lastname: Van Herp
authors.affiliation: Médecins Sans Frontières, Conakry, Guinea.
authors.forename: Marie-Claire
authors.initials: MC
authors.lastname: Kolié
authors.affiliation: Médecins Sans Frontières, Brussels.
authors.forename: Vesselina
authors.initials: V
authors.lastname: Yosifiva
authors.affiliation: Médecins Sans Frontières, Brussels.|Institute of Tropical Medicine, Antwerp, Belgium.
authors.forename: Severine
authors.initials: S
authors.lastname: Caluwaerts
authors.affiliation: Centers for Disease Control and Prevention.|Emory University Division of Pediatric Infectious Disease, Atlanta, Georgia.
authors.forename: Anita K
authors.initials: AK
authors.lastname: McElroy
authors.affiliation: Médecins Sans Frontières, Brussels.
authors.forename: Annick
authors.initials: A
authors.lastname: Antierens
mesh_terms: D000249:Adenosine Monophosphate / Q000031:analogs & derivatives; D000409:Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000998:Antiviral Agents / Q000008:administration & dosage*; D001769:Blood / Q000821:virology; D005260:Female; D019142:Hemorrhagic Fever, Ebola / Q000151:congenital* / Q000628:therapy*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D007231:Infant, Newborn; D011247:Pregnancy; D012265:Ribonucleotides / Q000008:administration & dosage*; D035703:Therapies, Investigational / Q000379:methods*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D000998:Antiviral Agents; D007155:Immunologic Factors; D012265:Ribonucleotides; C000594176:ZMapp; C000606551:remdesivir; D000249:Adenosine Monophosphate; D000409:Alanine
keywords: Ebola; GS-5734; ZMapp